Evidence map›Paper›PMID 34829304›Full record

ArticleDiagnostics (Basel, Switzerland)2021

The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study.

Cristina Marinela Oprean, Larisa Maria Badau, Robert-Alexandru Han, Teodora Hoinoiu, Gabriel-Mugur Dragomir, Daciana Grujic, Tiberiu Dragomir, Alis Dema

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Cristina Marinela OpreanANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.ORCID 0000-0001-5000-5422
Larisa Maria BadauDepartment of Oncology-ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.ORCID 0000-0002-2948-0365
Robert-Alexandru HanDepartment of Oncology-ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Teodora HoinoiuDepartment of Clinical Practical Skills, "Victor Babeş" University of Medicine and Pharmacy, Eftimie Murgu Square Nr.2, 300041 Timişoara, Romania.ORCID 0000-0001-7753-7621
Gabriel-Mugur DragomirDepartment of Teaching Training-POLYTEHNICAL, University of Timisoara, 300223 Timisoara, Romania.
Daciana GrujicDepartment of Plastic and Reconstructive Surgery, "Victor Babeş" University of Medicine and Pharmacy, Eftimie Murgu Square Nr.2, 300041 Timişoara, Romania.
Tiberiu DragomirDepartment V Internal Medicine, Discipline of Medical Semiology II, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square Nr.2, 300041 Timisoara, Romania.
Alis DemaANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With improved survival, more patients with prior breast cancer are at risk of having a second primary cancer diagnosed. The pattern and impact of second primary cancers following breast cancer is important for overall breast cancer therapeutic management. Our study is a first analysis of the trend of second primary tumours over time in terms of incidence, sites with significantly elevated risks and correlation with stage, molecular subtype and therapeutic strategies conducted in Eastern Europe in postmenopausal women with breast cancer. PATIENTS AND

methodsOur study population included 28 patients with prior breast cancer (BC) and second primary tumours, which were diagnosed and treated in our Institution between 2004 and 2017. The criteria for selection were based on the completeness of the documentation of the first treatment for breast cancer, stage of disease, molecular subtype, the site of origin of the second tumours and the survival data.

resultsAn increased risk of second primary cancer was associated with the 51-60 years age group (53.6%), with the greater prevalence in patients living in urban environments (82.1%). The use of chemotherapy increased the risk of the occurrence of gynecological second malignancies (75%). Our study is a first analysis of the trend of second primary tumours over time in terms of identifying sites with significantly elevated risks and correlation with therapeutic strategies conducted in Eastern Europe in postmenopausal women with breast cancer.

conclusionsOur study is a first analysis of the trend of second primary tumours over time in terms of correlation with luminal subtype and stage at diagnosis of primary cancer sites with significantly elevated risks and correlation with therapeutic strategies in postmenopausal women with breast cancer conducted in Eastern Europe. The reported time from primary to second primary malignancy onset, with a significantly higher rate for postmenopausal breast cancer patients, was less than one year (50%). With the advances and wider availability of genetic testing (e.g., gene panels), patients diagnosed with multiple primaries should be increasingly investigated for an underlying cancer predisposition. Postmenopausal women with breast cancer may benefit from increased surveillance and advice to avoid second malignancies.

Indexed as

breast cancerluminal subtypemolecular subtypepostmenopausal statussecond malignanciessecond primary tumour sites

Identifiers

PMID34829304
PMCPMC8622918
OpenAlexW3205495947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.